IMP4297

DRUG5 trials

Sponsors

Impact Therapeutics, Inc.

Conditions

Advanced Solid TumoursBreast CancerOvarian CancerPrimary Peritoneal CancerProstate CancerSolid Tumor

Phase 1

A Study of IMP4297 in Patients With Advanced Solid Tumors

CompletedNCT03508011

Impact Therapeutics, Inc.Advanced Solid Tumours, Breast Cancer, Ovarian Cancer +1

Start: 2017-08-23End: 2020-12-16Updated: 2021-03-30

The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors

CompletedNCT03507543

Impact Therapeutics, Inc.Advanced Solid Tumours, Breast Cancer, Ovarian Cancer +2

Start: 2017-02-03End: 2021-03-17Updated: 2021-03-30

IMP4297 Food Effect Trial in Healthy Volunteers

CompletedNCT04057729

Impact Therapeutics, Inc.Solid Tumor

Start: 2019-07-22End: 2019-09-27Updated: 2020-03-30

BA Study of IMP4297 (20mg vs 10mg) in Healthy Male Subjects

CompletedNCT04351165

Impact Therapeutics, Inc.Solid Tumor

Start: 2020-10-29End: 2021-04-30Updated: 2021-08-24

Phase 2

Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer

CompletedNCT04089189

Impact Therapeutics, Inc.Ovarian Cancer

Start: 2019-10-28End: 2024-12-17Updated: 2026-01-28

Related Papers

PR073/#425 Senaparib, a PARP inhibitor, in patients with BRCA1/2 mutated platinum sensitive recurrent ovarian cancer: subgroup analysis from Sabrina study

2023-11-01

Safety, Tolerability, and Pharmacokinetics of Senaparib, a Novel PARP1/2 Inhibitor, in Chinese Patients With Advanced Solid Tumors: A Phase I Trial

The Oncologist2023-06-205 citations

A phase 1 dose‐escalation study of the poly(ADP‐ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumors

Cancer2023-01-316 citations

Effect of Food on the Pharmacokinetics of Senaparib (IMP4297) in Healthy Chinese Subjects

Clinical Drug Investigation2022-10-141 citations

Pooled analysis of phase I dose-escalation and dose cohort expansion studies of IMP4297, a novel PARP inhibitor, in Chinese and Australian patients with advanced solid tumors.

Journal of Clinical Oncology2019-05-206 citations